查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
BCG 疫苗全球市场-2022-2029
市场调查报告书
商品编码
1140729

BCG 疫苗全球市场-2022-2029

Global BCG Vaccine Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

新兴和欠发达国家结核病患病率上升推动市场增长

世界许多地区，尤其是印度、中国和非洲等发展中国家和欠发达国家的结核病患病率不断上升，这将刺激对唯一一种针对这种疾病的疫苗——卡介苗疫苗的需求。我猜。根据《2020 年世界结核病报告》，大多数结核病病例发生在东南亚 (43%)、非洲 (25%)、西太平洋 (18%)、东地中海 (8.3%)、美洲 (3.0%) 和欧洲（3.0%）。2.3%）的份额较小。 30个高负担国家占全球估计发病率的86%，包括印度（26%）、中国（8.5%）、印度尼西亚（8.4%）、菲律宾（6.0%）和巴基斯坦（5.8%）、尼日利亚（4.6%）、孟加拉（3.6%）、南非（3.3%）等八个国家占世界总量的三分之二。新兴国家如此高的流行率在预测期内推动了卡介苗疫苗市场。

但是，卡介苗疫苗的一些副作用会对市场的增长产生负面影响。 BCG 疫苗对个人的副作用是预计在预测期内抑制全球市场增长的关键因素。此外，新兴国家卡介苗供应不足也是预计近期阻碍整体市场增长的因素之一。据美国泌尿外科协会称，美国唯一的 BCG 製造商默克公司已告知 AUA，由于全球范围内对 BCG 的使用和需求不断增长，该产品在全球范围内出现短缺。我正在通知您。作为回应，默克公司提高了卡介苗的产量，预计到 2020 年将持续出现剂量短缺。

地理渗透

在预测期内，亚太地区占据了绝大多数份额。

该研究按地区分析了全球市场的卡介苗疫苗市场，包括北美、欧洲、亚太地区、南美、中东和非洲。

在预测期内，亚太地区在全球卡介苗疫苗市场中占有很大的市场份额。在亚洲，预计印度在预测期内将出现显着增长。在印度，到 2021 年，所有年龄段的各种形式结核病的人均患病率为 312 人，其中德里所有形式的结核病患病率最高，为人均 747 人，古吉拉特邦最低，为人均 137 人。

此外，预计在预测期内，中东和非洲的价值将出现显着增长。由于该地区结核病患者人数的增加以及政府抗击结核病的力度加大，预计亚太地区的卡介苗疫苗市场将在预测期内快速增长。

竞争格局

由于疫苗生产的大规模发展，BCG 疫苗市场是一个竞争激烈的市场。为全球市场增长做出贡献的主要 BCG 疫苗製造商包括默克实验室、InterVax Ltd.、GreenSignal Bio Pharma Limited (GSBPL) 和 Statens Serum Institute。领先公司正在为 BCG 疫苗市场的全球增长采取新产品发布和扩张战略。 2021 年 1 月，默克在美国开设了一家新工厂，以扩大其 Tice BCG 製造能力。 2020 年 7 月，Serum Labs 对 BCG 疫苗进行了 3 期临床试验。印度血清研究所正在对其 BCG 候选疫苗 VPM1002 进行 3 期临床试验，以评估其在老年高危人群中减少 COVID-19 感染和严重后果的能力。 2020 年 9 月，印度血清研究所与比尔和梅琳达·盖茨基金会合作，为中低收入国家提供了 1 亿剂 COVID-19 疫苗。这种合作为印度血清研究所提供了增加製造能力的前期资金。这种合作将大大有助于加快 COVID-19 疫苗的开发并确保快速和全球获得。

COVID-19 对全球 BCG 疫苗市场的负面影响。

COVID-19 的爆发对全球 BCG 疫苗市场的增长产生了负面影响。在大流行期间，供应链中断对市场增长产生了重大影响。对 COVID-19 疫苗开发的日益关注导致 BCG 疫苗的除垢。因此，COVID-19 大流行正在抑制 2020 年 BCG 疫苗市场的市值。

全球 BCG 疫苗市场报告提供大约 55 个市场数据表、49 个图表和 170 页结构

内容

第 1 章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按产品划分的市场细分
  • 按人口统计的市场细分
  • 按应用划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 促进因素
      • 发展中国家和欠发达国家的结核病患病率不断上升
      • 全球出生率不断上升
    • 抑制因素
      • 卡介苗疫苗的副作用
    • 影响分析

第 5 章行业分析

  • 波特五力分析
  • 供应链分析
  • 价值链分析
  • PEST 分析
  • 定价分析
  • 监管分析
  • 保险报销分析
  • 未满足的需求
  • 专利趋势

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品分类

  • 免疫系统 BCG
  • 治疗性卡介苗

第 8 章按人口统计

  • 儿科（0-18 岁）
  • 成人（19-35 岁）

第 9 章按应用程序

  • 医院
  • 医务室

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第 12 章公司简介

  • Merck & Co.
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Sanofi Pasteur
  • Japan BCG Laboratory
  • China National Biotech Group
  • Serum Institute of India Pvt. Ltd
  • InterVax Ltd
  • GREENSIGNAL BIO PHARMA LIMITED（GSBPL）
  • STATENS SERUM INSTITUTE
  • Other companies（List Not Exhaustive）

第 13 章重要注意事项

第 14 章 DataM

简介目录
Product Code: DMHCIT3107

Market Overview

BCG Vaccine Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a highCAGR during the forecast period (2022-2029).

The only vaccine available to combat Tuberculosis is the Bacillus Calmette-Gurin (BCG) vaccine (TB). One dose is recommended for healthy babies near the time of birth in countries with a high incidence of Tuberculosis. However, only infants at high risk are usually immunized in areas where Tuberculosis is rare, while confirmed cases of Tuberculosis are personally screened and administered. It is also possible to immunize individuals who are not afflicted with Tuberculosis and who have not been recently immunized yet are also susceptible to drug-resistant Tuberculosis. The major factors propelling the growth of the BCG vaccine market are Increases in tuberculosis prevalence, especially in developing and underdeveloped countries, as well as technical developments in the field of vaccine research. Also, the rising birth rates across the globe, especially in China and India, contribute to the market's significant growth. Also, the rise in government policies and a global emphasis on immunization programs further drive demand growth. It is expected that untapped business opportunities in emerging regions can have multiple market growth prospects.

Market Dynamics: Increasing prevalence of Tuberculosis in developing and under-developed countries drives market growth

The increasing prevalence of Tuberculosis across the globe, especially in developing and under-developed countries such as India, China, and Africa, will stir the demand for the BCG vaccine as it is the only vaccine available for the disease. As per the global TB report 2020, most TB cases were in the WHO regions of South-East Asia (43%), Africa (25%) and the Western Pacific (18%), with smaller shares in the Eastern Mediterranean (8.3%), the Americas (3.0%) and Europe (2.3%). The 30 high TB burden countries accounted for 86% of all estimated incident cases worldwide, and eight of these countries accounted for two-thirds of the global total: India (26%), China (8.5%), Indonesia (8.4%), the Philippines (6.0%), Pakistan (5.8%), Nigeria (4.6%), Bangladesh (3.6%) and South Africa (3.3%). This high prevalence in emerging countries drives the market for BCG vaccines during the forecast period.

However, some side effects of the BCG vaccine adversely affect market growth. The side effects of the BCG vaccine among individuals are a key factor expected to curtail the global market's growth over the forecast period. Moreover, the shortage of supply in BCG vaccines in emerging countries is another factor expected to hinder the total market's growth in the near future. According to the American Urology Association, Merk and Company is the only producer of BCG in the United States informed the AUA that they were experiencing a global shortage of BCG due to the growing use and need for this product around the world. In comparison, Merck has raised the production of BCG as they expected the shortage of doses to carry through 2020.

Market Segmentation: The Immune BCG segment will project the fastest growth in the market throughout the forecast period

Based on the product, the BCG vaccine market has been classified into Immune BCG and Therapy BCG.

Immune BCG dominated the global market in 2021. Also, the Immune BCG is expected to present considerable growth shortly. BCG Vaccine is administered to newborns in the risk zone areas with a single dose of Immune BCG to prevent TB development. Therefore, the increasing usage of Immune BCG in the prevention of the development of TB is expected to propel segmental growth shortly.

BCG Vaccine is segmented on the basis of demographics, which includes Pediatrics (0-18 Years), Adults (19-35 Years).

The pediatrics (0-18 Years) segment held a significant market share in the forecast period. Pediatrics (0-18 Years) held the dominant position in the global market during the forecast period. In countries where the BCG vaccine is part of the national childhood immunization policy, BCG is normally offered to all children up to one year of age. In addition, older children (over 1 year of age) who have an elevated chance of contracting Tuberculosis should also be given this vaccine. It is rarely administered above 16 years of age and is never administered above 35 years of age since vaccines are only successful when administered at an early stage of life. It supports segment growth during the forecast period.

BCG Vaccine is segmented on the basis of Application, which includes Hospitals, Clinics, Others.

The hospital's segment held a significant market share in the forecast period. The administration of BCG vaccines done after the birth of a baby in the hospitals supports the segment growth during the forecast period. Moreover, the Clinics are expected to project a considerable CAGR during the forecast period. Older children (more than 1 year of age) who have an elevated risk of contracting Tuberculosis may also receive this vaccine administered at Clinics.

Geographical Penetration: Asia Pacific is the dominating region during the forecast period.

Based on geography, the study analyzes the BCG vaccine market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Asia Pacific region held a significant market share in the global BCG vaccine market in the forecast period. India is expected to represent considerable growth in Asia during the forecast period. In India, the prevalence of all forms of TB for all ages in India was 312 per lakh population in 2021, the highest prevalence for all forms of TB was 747 per lakh in Delhi, and the lowest was 137 per lakh population in Gujarat.

Moreover, the Middle East and Africa are expected to represent significant growth in value during the forecast period. BCG Vaccine market for the Asia Pacific is expected to observe rapid growth over the forecast period, backed by the growth of tuberculosis cases in the region coupled with increasing government initiatives to combat the disease.

Competitive Landscape:

The BCG vaccine market is highly competitive, owing to the presence of major developments in vaccine production. The key BCG Vaccine players which are contributing to the growth of the global market include Merck & Co., Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotech Group (a subsidiary of China National Pharmaceutical Group Corporation), Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited (GSBPL), and Statens Serum Institute among others. The major players are adopting new product launches and expansion strategies for global growth in the BCG Vaccine market. In January 2021, Merk constructed a new facility in the United States to expand manufacturing capacity for Tice BCG. In July 2020, the Serum institute conducted a phase 3 clinical trial for the BCG vaccine. The Serum Institute of India is conducting a phase III clinical trial of BCG vaccine candidate VPM1002 to evaluate its ability to reduce infection and severe disease outcomes of COVID-19 among high-risk persons of advanced age. In September 2020, the Serum Institute of India and Bill & Melinda Gates Foundation collaborated to make 100 million doses of COVID-19 vaccine available to low and middle-income countries. This collaboration provided upfront capital to Serum Institute of India to increase its manufacturing capacity. This collaboration majorly helps to boost the development of COVID-19 vaccines and ensure rapid, global access to them.

COVID-19 Impact: Negative impact on the global BCG vaccine market.

The outbreak of COVID-19 has negatively impacted the growth of the BCG vaccine market globally. The disruption in the supply chain has majorly impacted the growth of the market amidst the pandemic. The escalated focus on COVID-19 vaccine development has led to de-escalation in BCG vaccines. Therefore, the COVID-19 pandemic has hampered the market value of the BCG Vaccine market in 2020.

The global BCG vaccine market report would provide an access to approximately 55 market data tables, 49 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Demographics
  • 3.3. Market Snippet by Application
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Tuberculosis in Developing and under-developed countries
      • 4.1.1.2. Increasing birth rates across the globe
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects of BCG vaccine
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
  • 7.3. Market Attractiveness Index, By Product Segment
    • 7.3.1. Immune BCG*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Therapy BCG

8. By Demographics

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Demographics Segment
  • 8.3. Market Attractiveness Index, By Demographics Segment
    • 8.3.1. Pediatrics (0-18 Years)*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Adults (19-35 Years)

9. By Application

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 9.3. Market Attractiveness Index, By Application Segment
    • 9.3.1. Hospitals*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Clinics

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Demographics
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Demographics
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Demographics
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Demographics
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Demographics
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Merck & Co.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Sanofi Pasteur
  • 12.3. Japan BCG Laboratory
  • 12.4. China National Biotech Group
  • 12.5. Serum Institute of India Pvt. Ltd
  • 12.6. InterVax Ltd
  • 12.7. GREENSIGNAL BIO PHARMA LIMITED (GSBPL)
  • 12.8. STATENS SERUM INSTITUTE
  • 12.9. Other companies (List Not Exhaustive)

13. Premium Insights

14. DataM Intelligence Analysis

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us